In addition to the relative abundance of EGFR-mutations and ALK-rearrangements, the levels of phosphorylation of EGFR, ALK, or downstream proteins detectable in tumor samples by IHC have been proposed for predicting the efficacy of TKIs in NSCLC with EGFR/ALK co-alterations [125,128]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.